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Inrcrlcukin 2 (JL-2) is a lymphokine promoting immune response and thcrcfore has been investigated as an immunological adjuvant. In order to 
enhance the immunogenicity of recombinant viral protein, herpes simplex virus type 1 (HSV-I) glycoprotein D (gD), we gentically created a fusion 
protein consisting of gD and human IL-2. The fusion protein, without any other adjuvants, induced high antibody responses and cell-mediated 
immunity to HSV-I in mice. Mice immunized with the fusion protein were protected against HSV-1 infection. The results indicate that IL-Zfusing 
can provide a means for converting a weak immunogenic protein into a high immunogenic antigen, and the strategy would be widely applicable 
to the other antigens for pathogens. 
Interleukin 2; Fusion protein; Immunopotentiation; Glycoprotein D 
1. INTRODUCTION 
Recent technological advances have resulted in the 
production of safe subunit and synthetic peptide vac- 
cines against infectious diseases. Unfortunately, these 
antigens are usually not, or weakly, immunogenic in the 
absence of an immunological adjuvant [1,2]. Since 
many of these adjuvants cause unacceptable side ef- 
fects, only aluminium hydroxide (alum) is licensed for 
humans. However, alum is far from ideal; it only slight- 
ly increases cell-mediated immunity, and it requires 
refrigerated storage. In the studies to develop safe and 
effective adjuvants, interleukin 2 (IL-2) has been reveal- 
ed to enhance immune responses when the lymphokine 
was administered with antigens in animals (3-3). 
However, it shows only a marginal adjuvant effect 
because of its dispersion and short half-life in vivo. We 
assumed that IL-2 fused to proper antigens would be ef- 
ficiently delivered together with the antigens to the site 
at which the immune response occurred, and would ex- 
hibit full adjuvant activity even in vivo. On the basis of 
this hypothesis, we genetically constructed a novel fu- 
sion protein (t-gD-IL-2) consisting of truncated herpes 
simplex virus type 1 (HSV-1) envelope glycoprotein D 
(t-gD) fused with human IL-2 and then investigated its 
immunogenicity in mice. 
a polypeptide consisting of 394 amino acid residues was cloned from 
HSV-I strain ,Miyama (unpublished data). The Ncol-Hinfl fragment 
(0.83 kbp) was prepared from this fragment, following which a 
chemically synthesized EcoRl-Ncol adaptor (73 bp) was ligated to the 
Ncol site, and the Hinfl site was changed to a Nhel site using a syn- 
thetic Nhel linker (8 bp; Pharmacia). The resultant EcoRI-Nhel frag- 
menr (0.9 kbp) included the truncated gD (t-gD) gene coding for 
amino acid residues I to 301 from the N-terminus. The HgiAl-BanrHI 
fragment (0.43 kbp) including mature IL-2 gene which coded for 133 
amino acid residues excluding a signal sequence was prepared from 
the plasmid pTB399 [6] (4.5 kbp) which expressed the IL-2 gene under 
the control of murine leukemia virus long terminal repeat (MuLV 
LTR). The HgiAl site was then changed to a Nhel she using the N/WI 
linker. The two fragments containing t-gD and IL-2 gene were 
simultaneously inserted inro the EcoRl and &/II site of pTB399 to 
give plasmid pHDL201 (5.4 kbp). An expression plasmid, pHDLdhfr1 
(7.4 kbp), was consequently constructed as follows: the C/al fragment 
(2.9 kbp) of pHDL2Ol was ligated with a C/al-digested pTB348 [7] 
(4.5 kbp) which was the expression plasmid for the hamster 
dehydrofolate reductase (DHFR) gene under the control of SV40 early 
promoter. Another plasmid, pSHD-dhfrl (7.0 kbp), for expressing 
the t-gD gene alone was similarly constructed as a control. All enzymes 
used for constructing plasmids and plasmic vcc[ors were pulshascd 
from Takara Shuzo Co. Ltd. (Kyoro, Japan). 
2, MATERIALS AND METHODS 
2.1, Consrnrcriotr of rlrc piastnicl fur c.~/~cssirr# I-gD4L-2 
The Daa,trHi fragment (6.6 kbp)conteirting gD gene which coded for 
2.2. Preparation o/ I-gD-IL-2 expressed in CHO cells 
Theexpression plasmid, pHDLdhfrl or pHSDdhfr1, was introduc- 
cd into DHFR’ CHO cells, and then high-producer clones which 
secreted anrigens a~ the lcvcl of several mg/litcr in a strum-free 
medium, ASFIO4 (Ajinomoto, Japan), were established by amplifica- 
tion with 20 PM of mc!hotrcxa1c (Sigma). The oullurc supcrnatant (5 
lircr) was applied to a Butyl-Toyopcal 6501M (Tosoh Co., Ltd., Japan) 
column. The antigens wcrc fractionated wiUi a linear gradient of 
saturnrcd ammonium sulfate from 20 to 0%. t-gD and I-gD-IL-2 were 
clutccl at 5 and 2%, rcspcctively. Finally, each fraction was applied to 
a Scplraeryl S-300 (Pharmacia) column, and then clurcd ivith Dulbcc- 
co’s phospl,arc-buffered saline (PBS). 
Curfe3/Jot&rre &&w: M. Harnnm, tfiotrct~nology Rctc;trch 2.3. ~!c/srffet~/crtr uf art&IiSV uttlibody titers 
Laboratarlcr, Research and Dcvclopnicnt Division, Takcda Chemical 
Indu>lrirr, Ltd.. Osaka 532, Japan. Fax: (81) (6) 300 6276. 
Anti-HSV antibody liter (IgG) was dclcrmincd with a commercially 
wtlilablc klr (Hcrpcr SW; Wittakcr Uioproductr, USA) for dc~cc. 
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ting antibodies to HSV-I and -2 with some modification. Microplates 
coated with inactivated HSV-1 and -2 were blocked with PBScontain- 
ing 2Oc70 fetal calf serum (FCS) at room temperature for 2 h. Test sera 
diluted serially twofold with Tris-HCI buffer (40 mM Tris-HCI 
(pH7.5), 5% NaCI, 0.05% Tween 20, 20% FCS) were incubated on 
the plates at room temperature for 1 h. IgG bound to the plates were 
detected with horseradish peroxidase-conjugated rabbit anti-mouse 
1gG antibody (Zymed). Antibody titers were determined on the basis 
of the probit analysis [8]; a purified mouse monoclonal IgG antibody 
to gD, M42. was used as a reference. The titer of the reference (1.9 
mg/ml) was arbitrary defined as 1.9 U/ml. Data represent mean 
values *SD for 10 mice. 
2.4. Cytclytic assays 
Cell culture and analysis of killer activity were carried out accor- 
ding to the method reported previously [7]. Spleen sells were infected 
with 1 x 10’ plaque-forming units (pfu) of HSV-1 strain Miyama. 
The WW-1-intected or uninfected spleen cells were suspended at 2.5 
x IO6 cells/ml in complete RPM1 1640 medium containing 10% FCS 
(50 ml), and were cultured at 37’C for 5 days under humidified 5% 
CO2 in air. After the cells were washed, viable cells were counted and 
adjusted to the proper concentration. A syngeneic macrophage cell 
line. P388 [9], was used. In order to prepare HSV-infected target cells, 
P388 cells (4 x 106) were infected with HSV-I Miyama strain at the 
multiplicity of infectious dose of 1, and incubated at 37°C For 1 h. 
After the infection, these cells were immediately labelled with “Cr. 
Uninfected P388 cells were similarly labelled with “Cr. The effector 
spleen cells were mixed with the HSV-l-infected or uninfected target 
cells at the indicated ratio, and were incubated in microplates at 37’C 
for 4 h. Lysis of the target cells was determined from the amounts of 
“Cr released into the culture supernatant. Data represent mean values 
in duplicate assays. 
3. RESULTS AND DISCUSSION 
As shown in Fig. 1, we constructed a plasmid, 
pHDLdh.frl, to express the fusion protein composed of 
gD and human IL-2 in mammalian cells: the IL-2 gene 
excluding the signal sequence was fused to the truncated 
gD (t-gD) gene from which the coding sequence of the 
C-terminal region including the transmembrane (TM) 
domain had been removed. Another plasmid to express 
t-gD alone was similarly constructed as a control. These 
plasmids were introduced into Chinese hamster ovary 
(CHO) cells, and clones secreting t-gD or IL-2-fused t- 
gD (t-gD-IL-2) into the culture supernatant were 
established. These antigens were purified by the pro- 
cedure consisting of hydrophobic column chromato- 
graphy and gel-filtration. The purity of t-gD and t-gD- 
IL-2 was estimated to be 95 and 79%, respectively from 
densitometric analyses (Fig. 2). t-gD-IL-2 could support 
growth of IL-2-dependent cells in vitro, indicating that 
the fused IL-2 retained its biological activity (37% of 
specific activity compared with recombinant human 
IL-2). 
We immunized BALB/c and C57BL/G mice sub- 
cutaneously (s.c.) with t-gD, t-gD mixed with recombi- 
nant human IL-2 (rIL-2), ‘t-gD-IL-2, or t-gD adsorbed 
on alum, and then evaluated serum anti-HSV antibody 
responses by enzyme immunoassay (EIA) (Table I). 
After a primary immunization, t-gD alone induced little 
anti-HSV antibody production in both strains. Although 
the rnixturc of t-gD and rIL-2 elicited several times 
Signal TM 
i 
: 
\ I 
\ 
\ 
\ t-gD-IL-2 / 
Amp’ 
MuLV LTR 
DH 
Fig. I. Construction of t-gD-IL-2 expression plasmid. Abbreviations 
represent as follows; TM = transmembrane domain, E = EcoRl, 
N = Nhel, B = BamHl, Bg = Bglll, C = Clal, Poly A = polyadenilation 
site. 
higher response than t-gD alone in BALB/c mice, it 
only slightly induced the antibody production in 
C57BL/6 mice. In contrast, t-gD-IL-2 remarkably in- 
duced the antibody production in both strains: it was 27 
to 77 times more potent than t-gD alone, and 17 to 20 
times more potent than the mixture of t-gD and rIL-2 in 
Fig. 2. Elcctrophorctic analysis of Purified t.gD-IL-2. The purified 
antigens wcrcelcctrophorcrcd on a 12% polyacrylamidc SDS gel 1141, 
followed by Coomasic blue staining, Lanes correspond to 10 pg of 
purified (l)t-gD and (2)t.gD-IL-2. The molecular weight of tqtD and 
t-gD-IL-2 were about 40 000 and 54 Ooo, rcspcctivcly. Dcnaitomctric 
analysts wcrc pcrformcd using a Vidco.densitl,lnctcr (So-Had). 
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Table I 
Efficient production of anti-HSV antibody in mice immunized with t-gD-IL-2 
Anti-HSV antibody titer (mU/ml) 
Antigen 
(BALB/c mice) 
Control 
t-gD 
Mixture of 
t-gD and rlL-2b 
t-gD-IL-2 
t-gD adsorbed 
on alumC 
Primary (dose/mouse) 
1 /rP 5 lrg 
<7 nd 
c IS 9*4 
23 -c 29 35 f 38 
400 f 292 692 -c 442 
341 -c 267 481 & 451 
Secondary (dose/mouse) 
1 ai2 
nd 
1,018 f 1,833 
nd 
46,183 * 38,443 
nd 
(CS7BL/6 mice) 
Control 
t-gD 
Mixture of 
t-gD and rIL-2 
t-gD-IL-2 
t-gD adsorbed 
on alum 
< 14 nd 
< 14 nd 
c 14 nd 
1,465 f 802 nd 
88 -I 120 nd 
nd 
nd 
nd 
nd 
nd 
“Eight-week-old female BALB/c or C57BL/6 mice (IO/group) were S.C. immunized with the in- 
dicated antigens in 200 ~rl PBS. Control mice were injected with PBS alone. Taking the purity into 
consideration, the amounts of purified t-gD and t-gD-IL-2 were properly adjusted to give the in- 
dicated doses. For the primary response, mice were bled 5 weeks after the immunization. For the 
secondary response, mice were primarily immunized with t-gD or t-gD-IL-2 at the indicated dose, 
and 4 weeks later they received a secondary immunization of the same dose. Sample sera were 
prepared 2 weeks after the secondary immunization. 
brlL-2 was mixed with the indicated dose of t-gD in the molar ratio of 1 : 1. i.e. 0.25 fig and 1.25 
ag of rlL-2 were added to 1 Pg and 5 ag of t-gD, respectively. 
‘Alum (100 pg) was admixed with the indicated doses of t-gD. nd, not done. 
Table 11 
Induction of killer cells in spleen cells immunized in vivo with t-gD-IL-2 after in vitro stimulation with HSV-1 
Lysis (To) 
Immunization 
in vivo 
Stimulation with 
HSV-I in vitro 
HSV-1 infection 
of target cells 25 
Effcctor/target ratio 
50 100 
Control 
+ 
+ 
t-gD 
+ 
.I- 
Mixture of 
t-gD and rlL-2 
+ 
t 
t-gD-IL-2 
t 
t 
- 
-I- 
d- 
+ 
c 
-I- 
+ 
+ 
+ 
<I 
<I 
Cl 
Cl 
<I 
<I 
<I 
Cl 
<I 
<I 
nd 
Cl 
<I 
Cl 
14.7 
26.5 
<I 
<I 
<I 
<I 
<I 
<I 
<I 
<I 
<I 
<I 
nd 
Cl 
Cl 
Cl 
19,7 
34.3 
<I 
<I 
<I 
<I 
nd 
<I 
nd 
<I 
<I 
<I 
nd 
nd 
<I 
<I 
24.8 
38.7 
BALB/c mice 4/group) wcrc immunized with t-gD, n mixture of t-gD and rIL-2, or t-gD-IL-2 at a dose of 5 ~g/mouac in the same manner as 
dcscribcd in the footnote of Tnblc 1. Control mice wcrc immunlscd with PBS alone. Five weeks after the Immunisation, spleen cells wcrc obtained 
front each group of mice and pooled. nd, 1101 done. 
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BALE/c mice; furthermore, it was at least 100 times 
more potent than tgD alone or tgD mixed with rIL-2 in 
C57BL/6 mice. Upon a secondary immunization, t-gD- 
IL-2 was 45 times more potent than t-gD alone in 
BALB/c mice. These results demonstrated that the fus- 
ed IL-2, but not the IL-2 mixed with the antigen, acts as 
an extremely potent adjuvant, although the responses 
differed somewhat between the two strains. in addition, 
the fused IL-2 was comparable to or slightly more po- 
tent than alum in BALB/c mice; however, it was 17 
times more potent than alum in C57BL/4 mice. 
Although anti-HSV antibody titers were measured by 
the ELISA method, we observed that these antibody 
titers almost corresponded to significance of virus 
neutralizing activities (unpublished). The mechanism by 
which alum exhibits its adjuvant effecl is generally 
thought to depend on creating a depot at the injection 
site, and it prolongs the release of antigens and 
stimulates antigen presenting cells [ 1, lo]. However, the 
fused IL-2 is expected to act in a different way. In fact, 
l we have observed that t-gD-IL-2 can elicite the specific 
antibody production upon intravenous administration. 
In addition, t-gD-IL-2 and alum synergistically enhanc- 
ed the antibody production (unpublished). 
We next examined whether t-gD-IL-2 could induce 
cell-mediated immunity. BALB/c mice were immunized 
with t-gD, a mixture of t-gD and rlL-2, or t-gD-IL-2. 
The primed spleen cells were then assayed for in vitro 
cytotoxity. As shown in Table II, spleen cells obtained 
from mice immunized with t-gD-IL-2, but not t-gD or 
the mixture of t-gD and rlL-2, showed apparent killer 
activity against both I-ISV-infected and uninfected P388 
target cells when restimulated with HSV-1. The percen- 
tage of lysis in HSV-l-infected target cells was higher 
than that in uninfected target cells, indicating that both 
non-specific and HSV-l-specific killer cells were induc- 
ed in the spleen cells immunized with t-gD-IL-2. Since 
the target used here was a macrophage cell line, [9] and 
the killer cells failed to lyse HSV-l-infected syngenic 
fibroblast cells (unpublished), the specific killing was 
thought to be major histocompatibility complex class 
.lI-restricted. ‘&%ese results indicated that t-gD-IL-2 
could efficiently induce cell-mediated immunity as well 
as humoral immunity. 
Such a highly immunogenic property of t-gD-IL-2 
was shown in response to live virus challenge. Fig. 3 
shows that mice immunized with 1 pg of t-gD-IL-2 were 
protected from lethal HSV-I infection. Most mice im- 
munized with t-gD died within 6-13 days after virus in- 
oculation. Immunization with the mixture of t-gD and 
rIL-2 could reduce the incidence of HSV-I infection, 
while most mice immunized with t-gD-IL-2 survived 
during the cxpcrimental period, although one mouse 
died on day 11. IL-2 was shown to protect neonatal 
mice from lethal HSV infection [I 11, and treatment of 
HSV-infected guinea pigs with IL-2 reduced the fre- 
qucncy and severity of genital recurrences [ 121. In addi- 
0 5 10 15 
Days alter inoculation 
Fig. 3. Protection of BALE/c mice from HSV infection by immuniza- 
tion with t-gD-IL-2. BALE/c mice were S.C. immunized with t-gD 
(m), a mixture of t-gD and rlL-2 (a) or t-gD-IL-2 ([J) at a dose of 1 
ag/mouse in the same manner as described in the footnote of Table 
I. Control mice were injected with PBS alone (0). Five weeks after 
the immunization, the mice were intraperitoneally inoculated with 
2x I@ pfu of HSV-1 strain Miyama (100 LD50) and then monitored 
daily for a period of 17 days. A number of parenthesis represents the 
symptomatical and dead mice per total mice. 
tion, we preliminary observed that the mice ad- 
ministered with t-gD-IL-2, but not t-gD, after HSV-1 
inoculation, were completely protected against viral in- 
fection even in drug-induced immunosuppressive state 
(unpublished). Thus, we think that t-gD-IL-2 may be a 
useful immunotherapeutic agent against recurrent HSV 
disease, because immunosuppression is thought to be a 
major trigger of recurrence of HSV [13]. 
In this study we demonstrated that IL-2 fused to the 
proper antigen could exhibit very potent adjuvant ac- 
tivity in vivo. As a possible mechanism, the prolonged 
serum half-life of antigen-fused IL-2 might interpret he 
high immunogenicity of t-gD-IL-2. However, t-gD-IL-2 
showed only marginal aduvant effect on antibody 
response to human serum albumin when the unrelated 
antigen was administered with t-gD-IL-2 (unpublishedj. 
Alternatively, IL-2 delivered together with t-gD to 
regional lymphoid tissues may efficiently activate the 
gD-specific lymphocytes. We think that the lymphokine 
fused with the antigen would be useful as a safe adju- 
vant to overcome the various drawbacks associated 
with the conventional adjuvant, alum. Our strategy 
reported here would be widely applicable to other an- 
tigens and lymphokines. 
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